XALKORI has received approval in Switzerland.

XALKORI® (crizotinib) is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that is advanced or has spread to other parts of the body and is caused by a defect in a gene called ALK (anaplastic lymphoma kinase). XALKORI approval is based on the percentage of patients whose tumors responded to treatment.

It is not known whether XALKORI will improve symptoms or will help patients with this disease live longer. It is not known if XALKORI is safe and effective in children.

For more information and full prescribing information please visit www.XALKORI.com